Nick Paul Taylor

4 days ago | fiercebiotech.com | Nick Paul Taylor

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease prospect to its late-phase pipeline. The Financial Times reports Merck submitted a nonbinding offer that valued MoonLake at more than $3 billion earlier this year. The offer was rejected, but talks could be revived, the FT said.

4 days ago | biospace.com | Nick Paul Taylor

Roche and Jazz Pharmaceuticals have shared updated Phase III data on a combination of their medicines Tecentriq and Zepzelca, furthering plans to win FDA approval for the drug cocktail in small cell lung cancer in a first-line maintenance setting this year. Investigators shared the results in an abstract for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and a paper published in The Lancet.

5 days ago | biospace.com | Nick Paul Taylor

Sanofi has struck a $9.5 billion deal to buy Blueprint Medicines for an approved rare disease drug and an early-stage immunology pipeline. The deal, $9.1 billion of which is upfront, will give Sanofi ownership of the systemic mastocytosis therapy Ayvakit. Blueprint posted net product revenues of $479 million in 2024 and, after achieving 61% growth in the first quarter, recently raised its guidance for this year to between $700 million and $720 million.

5 days ago | medtechdive.com | Nick Paul Taylor

This audio is auto-generated. Please let us know if you have feedback. Bivacor has received breakthrough designation for its titanium total artificial heart, the company said Friday. The Food and Drug Administration designation could accelerate development of a device that recently kept a man alive for more than 100 days while he waited for a donor heart. Syncardia already sells an artificial heart, and Realheart and Carmat are developing total artificial hearts.

5 days ago | fiercebiotech.com | Nick Paul Taylor

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading candidates in the hottest area of immuno-oncology. BioNTech is tucked in behind Summit Therapeutics in the race to bring a PD-1/L1xVEGF-A bispecific to the U.S. market.